HC Wainwright Analysts Lift Earnings Estimates for DNTH

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Stock analysts at HC Wainwright lifted their Q1 2025 earnings per share (EPS) estimates for shares of Dianthus Therapeutics in a research report issued to clients and investors on Wednesday, March 12th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($1.03) per share for the quarter, up from their previous forecast of ($1.21). HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q2 2025 earnings at ($1.10) EPS, Q3 2025 earnings at ($1.05) EPS, Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($4.07) EPS and FY2026 earnings at ($4.60) EPS.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04. The firm had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.40 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%.

DNTH has been the subject of a number of other reports. TD Cowen assumed coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They set a “buy” rating for the company. Wedbush reissued an “outperform” rating and set a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Guggenheim reissued a “buy” rating and set a $84.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $52.14.

Dianthus Therapeutics Stock Performance

NASDAQ:DNTH opened at $20.74 on Monday. The stock has a fifty day moving average price of $22.34 and a 200-day moving average price of $24.70. The company has a market cap of $613.84 million, a price-to-earnings ratio of -8.30 and a beta of 1.82. Dianthus Therapeutics has a fifty-two week low of $18.13 and a fifty-two week high of $33.77.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Quest Partners LLC grew its position in shares of Dianthus Therapeutics by 112,400.0% in the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after buying an additional 1,124 shares during the last quarter. R Squared Ltd bought a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at about $26,000. KLP Kapitalforvaltning AS bought a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at about $33,000. KBC Group NV bought a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at about $35,000. Finally, BNP Paribas Financial Markets bought a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at about $59,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.